You searched for metabolic diseases - Page 57 of 63

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

…new partnerships examples of lows…I can therefore only speculate this mysterious ‘disease area’ is likely in the metabolic and chronic field, such as diabetes. We shall see soon, I suppose….

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 1 Feb 2023

Advancing cancer care with 3D genomics

…types, including genomic, epigenomic, transcriptomic, proteomic, and metabolic profiles. It relies on the belief that subsequent machine learning data analyses will capture meaningful insights from this data, despite there often…

February 1, 2023 - 7 minutesmins - By External Contributor

In Depth 20 Mar 2024

Are molecular glues the key to undruggable targets?

…coined more than three decades ago, and its potential impact in treating diseases has been realized for a while now, however, developing them has proven to be quite challenging. This…

March 20, 2024 - 9 minutesmins - By Roohi Mariam Peter

News and Trends 21 Apr 2017

The World’s Most Expensive Drugs have European Owners

A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon…

April 21, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 8 Nov 2022

Rallybio announces positive phase 1 results for drug treating PNH and gMG

…diseases. Since its launch in January 2018, it has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology,…

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Aug 2024

GLP-1 shortage: Can biotech companies keep up with rising demand?

…added Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA, in a press release. Moreover, Lilly’s main contender, the Danish multinational Novo Nordisk, is investing…

August 28, 2024 - 6 minutesmins - By Roohi Mariam Peter

News and Trends 25 Jul 2023

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

…transform the landscape for patients with severe cardiovascular diseases,” said Yvonne Greenstreet, chief executive officer of Alnylam. “With this collaboration, we now can develop zilebesiran in a more robust way,…

July 25, 2023 - 5 minutesmins - By Jim Cornall

In Depth 23 May 2022

The coming of age of European synthetic biology

…human consumption. “Investors see the promise behind synbio being able to produce many molecules in a much more sustainable and efficient way. With synbio, any metabolic pathway is theoretically accessible…

May 23, 2022 - 8 minutesmins - By Helen Albert

News and Trends 23 Jan 2018

NASH Leader goes Pediatric with Clinical Trial Launch in US

The FDA has cleared Genfit to kick off clinical trials to see if its NASH drug, elafibranor, can also help children. Genfit develops diagnostic and therapeutic tools for metabolic and…

January 23, 2018 - 2 minutesmins - By Alex Dale

News and Trends 11 Dec 2015

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

…on 3 therapeutic areas: metabolic, gastrointestinal and cardiovascular diseases. At present, Zealand has one marketed product through a development partnership with Sanofi, Lixisenatide, a treatment of type II diabetes, along…

December 11, 2015 - 2 minutesmins - By Philip Hemme

In Depth 4 Mar 2025

The biggest biotech funding rounds in February 2025

…total. And, thanks to Abcuro’s $200 million financing round, the autoimmune diseases subsector brought in the second-largest amount of funding last month, despite there only being one round. Public biotech…

March 4, 2025 - 4 minutesmins - By Willow Shah-Neville

In Depth 11 Aug 2022

Biosecurity is synthetic biology’s most crucial ally

…at Ginkgo Bioworks, HydGene Renewables and Eden Brew, the community is working on solutions for such eventualities. “Physical containment, integrated kill switches and metabolic dependencies, for instance, provide technical control…

August 11, 2022 - 6 minutesmins - By Kostas Vavitsas

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: metabolic diseases

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Advancing cancer care with 3D genomics

Are molecular glues the key to undruggable targets?

The World’s Most Expensive Drugs have European Owners

Rallybio announces positive phase 1 results for drug treating PNH and gMG

GLP-1 shortage: Can biotech companies keep up with rising demand?

Roche and Alnylam to work on RNAi therapeutic to treat hypertension

The coming of age of European synthetic biology

NASH Leader goes Pediatric with Clinical Trial Launch in US

Biotech of the Week: Zealand Pharma, Biotech Success Story made in Denmark

The biggest biotech funding rounds in February 2025

Biosecurity is synthetic biology’s most crucial ally

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!